Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Value Market Research | PRODUCT CODE: 2105716

Cover Image

PUBLISHER: Value Market Research | PRODUCT CODE: 2105716

Global Cancer Testing Screening Market Size, Share, Trends & Growth Analysis Report 2026-2034

PUBLISHED:
PAGES: 263 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 3920
PDF & Excel (10-user License)
USD 4730
PDF & Excel (Corporate User License)
USD 7430

Add to Cart

The global cancer testing screening market size is expected to reach USD 362.98 Billion in 2034 from USD 202.66 Billion in 2025, growing at a CAGR of 6.69 during 2026-2034.This market is witnessing robust growth as healthcare providers emphasize early disease detection to improve treatment outcomes and patient survival. Cancer testing and screening technologies enable timely identification of various cancers through imaging, laboratory diagnostics, molecular testing, and genetic analysis. Rising cancer prevalence, increasing public awareness, and expanding government screening initiatives are encouraging widespread adoption of advanced diagnostic solutions. Improvements in healthcare accessibility are also contributing to stronger market development.

Technological advancements in molecular diagnostics, liquid biopsy, genomic sequencing, and artificial intelligence-assisted imaging are transforming cancer detection capabilities. Healthcare organizations are investing in precision medicine and personalized diagnostic approaches to improve diagnostic accuracy and treatment planning. Growing research activities, supportive reimbursement policies, and increasing collaboration between biotechnology companies and healthcare institutions are accelerating innovation. Expansion of preventive healthcare programs continues to strengthen demand for comprehensive screening services.

The future outlook remains highly encouraging as early detection becomes an essential component of global cancer control strategies. Integration of artificial intelligence, digital pathology, and biomarker-based diagnostics will enhance screening accuracy and efficiency. Expanding healthcare infrastructure in developing economies and increasing investments in oncology research will create significant opportunities. Continuous innovation in diagnostic technologies will support more effective and accessible cancer screening worldwide.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • Diagnostics
  • Screening

By Cancer Type

  • Respiratory System Cancer
  • Leukemia
  • Myeloma and Lymphoma
  • Skin Cancer
  • Abdominal/Digestive System Cancer
  • Genital Cancer
  • Oral Cancer
  • Urinary System Cancer
  • Endocrine System Cancer
  • Breast Cancer
  • Others

By Technique

  • Imaging
  • Biopsy
  • Genomic and Molecular Tests (Next-Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others)

By Product Type

  • Molecular Diagnostics
  • Companion Diagnostics

By Stage

  • Terminal
  • Stage 0-4
  • Prognosis
  • Other Staging System

By Gender

  • Male
  • Female

COMPANIES PROFILED

  • Thermo Fisher Scientific, Illumina, Exact Sciences, Guardant Health, Hologic, Bio-Rad, Danaher, Agilent Technologies, Myriad Genetics, Invitae, Natera, Fujifilm, Olympus, Eiken Chemical, Labcorp
Product Code: VMR112119237

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER TESTING SCREENING MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER TESTING SCREENING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Cancer Type
  • 5.2. Respiratory System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Myeloma and Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Abdominal/Digestive System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Genital Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Oral Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.9. Urinary System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.10. Endocrine System Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.11. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.12. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER TESTING SCREENING MARKET: BY TECHNIQUE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Technique
  • 6.2. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Biopsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Genomic and Molecular Tests (Next-Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER TESTING SCREENING MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Product Type
  • 7.2. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Companion Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CANCER TESTING SCREENING MARKET: BY STAGE 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Stage
  • 8.2. Terminal Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Stage 0-4 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Prognosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.5. Other Staging System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CANCER TESTING SCREENING MARKET: BY GENDER 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Gender
  • 9.2. Male Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Female Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CANCER TESTING SCREENING MARKET: BY REGION 2022-2034 (USD MN)

  • 10.1. Regional Outlook
  • 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.2.1 By Type
    • 10.2.2 By Cancer Type
    • 10.2.3 By Technique
    • 10.2.4 By Product Type
    • 10.2.5 By Stage
    • 10.2.6 By Gender
    • 10.2.7 United States
    • 10.2.8 Canada
    • 10.2.9 Mexico
  • 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.3.1 By Type
    • 10.3.2 By Cancer Type
    • 10.3.3 By Technique
    • 10.3.4 By Product Type
    • 10.3.5 By Stage
    • 10.3.6 By Gender
    • 10.3.7 United Kingdom
    • 10.3.8 France
    • 10.3.9 Germany
    • 10.3.10 Italy
    • 10.3.11 Russia
    • 10.3.12 Rest Of Europe
  • 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.4.1 By Type
    • 10.4.2 By Cancer Type
    • 10.4.3 By Technique
    • 10.4.4 By Product Type
    • 10.4.5 By Stage
    • 10.4.6 By Gender
    • 10.4.7 India
    • 10.4.8 Japan
    • 10.4.9 South Korea
    • 10.4.10 Australia
    • 10.4.11 South East Asia
    • 10.4.12 Rest Of Asia Pacific
  • 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.5.1 By Type
    • 10.5.2 By Cancer Type
    • 10.5.3 By Technique
    • 10.5.4 By Product Type
    • 10.5.5 By Stage
    • 10.5.6 By Gender
    • 10.5.7 Brazil
    • 10.5.8 Argentina
    • 10.5.9 Peru
    • 10.5.10 Chile
    • 10.5.11 Rest of Latin America
  • 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 10.6.1 By Type
    • 10.6.2 By Cancer Type
    • 10.6.3 By Technique
    • 10.6.4 By Product Type
    • 10.6.5 By Stage
    • 10.6.6 By Gender
    • 10.6.7 Saudi Arabia
    • 10.6.8 UAE
    • 10.6.9 Israel
    • 10.6.10 South Africa
    • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

  • 11.1. Recent Developments
  • 11.2. Company Categorization
  • 11.3. Supply Chain & Channel Partners (based on availability)
  • 11.4. Market Share & Positioning Analysis (based on availability)
  • 11.5. Vendor Landscape (based on availability)
  • 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL CANCER TESTING SCREENING INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Company Profiles
    • 12.2.1 Thermo Fisher Scientific
    • 12.2.2 Illumina
    • 12.2.3 Exact Sciences
    • 12.2.4 Guardant Health
    • 12.2.5 Hologic
    • 12.2.6 Bio-Rad
    • 12.2.7 Danaher
    • 12.2.8 Agilent Technologies
    • 12.2.9 Myriad Genetics
    • 12.2.10 Invitae
    • 12.2.11 Natera
    • 12.2.12 Fujifilm
    • 12.2.13 Olympus
    • 12.2.14 Eiken Chemical
    • 12.2.15 Labcorp
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!